Readout LOUD podcast: Trump’s ‘most-favored nation’ plan

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

How likely is it for President Trump’s new drug-pricing plan to be implemented? Why have investors seemed unbothered by the proposal? And will we see a return of Elizabeth Holmes’ blood-testing ambitions?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We chat about the mixed sentiment in biotech markets these days and a new blood-testing company formed by Holmes’ husband.

We also bring on STAT’s D.C. correspondent Daniel Payne to talk about Trump’s “most-favored nation” drug pricing policy and health secretary Robert F. Kennedy Jr.’s recent congressional hearing.

For more on Trump’s drug-pricing policy, go here; to read more on the key questions surrounding the proposal, go here; for more on Kennedy’s hearings, go here and here; and to learn more the new blood-testing company, go here and here.

Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts.